Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brady

Showing results (421-430 of 627) with videos related to

Pageof 63
Sort By:
Journal of Hepatology|August 11, 2023
A common variant that alters SUN1 degradation associates with hepatic steatosis and metabolic traits in multiple cohortsKapil K Upadhyay, Xiaomeng Du, Yanhua Chen, et al.
Nature|December 5, 2023
Author Correction: Bacterial cGAS senses a viral RNA to initiate immunityDalton V Banh, Cameron G Roberts, Adrian Morales-Amador, et al.
Nature|November 15, 2023
Bacterial cGAS senses a viral RNA to initiate immunityDalton V Banh, Cameron G Roberts, Adrian Morales-Amador, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyP M Fracasso, M F Brady, D H Moore, et al.
Journal of Medical Genetics|June 24, 2020
UKCGG Consensus Group guidelines for the management of patients with constitutional <i>TP53</i> pathogenic variantsHelen Hanson, Angela F Brady, Gillian Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group studyD R Barnhill, R J Kurman, M F Brady, et al.
Cancer|February 15, 1993
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group studyF J Major, J A Blessing, S G Silverberg, et al.
Nano Letters|February 4, 2014
Ultrafast phase transition via catastrophic phonon collapse driven by plasmonic hot-electron injectionKannatassen Appavoo, Bin Wang, Nathaniel F Brady, et al.
Gynecologic Oncology|September 8, 2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterusAaron H Wolfson, Mark F Brady, Thomas Rocereto, et al.
Pageof 63

Showing results (421-430 of 627) with videos related to

Sort By:
Pageof 63
Journal of Hepatology|August 11, 2023
A common variant that alters SUN1 degradation associates with hepatic steatosis and metabolic traits in multiple cohortsKapil K Upadhyay, Xiaomeng Du, Yanhua Chen, et al.
Nature|December 5, 2023
Author Correction: Bacterial cGAS senses a viral RNA to initiate immunityDalton V Banh, Cameron G Roberts, Adrian Morales-Amador, et al.
Nature|November 15, 2023
Bacterial cGAS senses a viral RNA to initiate immunityDalton V Banh, Cameron G Roberts, Adrian Morales-Amador, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2001
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group studyP M Fracasso, M F Brady, D H Moore, et al.
Journal of Medical Genetics|June 24, 2020
UKCGG Consensus Group guidelines for the management of patients with constitutional <i>TP53</i> pathogenic variantsHelen Hanson, Angela F Brady, Gillian Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group studyRobert C Young, Mark F Brady, Roberta K Nieberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1995
Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group studyD R Barnhill, R J Kurman, M F Brady, et al.
Cancer|February 15, 1993
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group studyF J Major, J A Blessing, S G Silverberg, et al.
Nano Letters|February 4, 2014
Ultrafast phase transition via catastrophic phonon collapse driven by plasmonic hot-electron injectionKannatassen Appavoo, Bin Wang, Nathaniel F Brady, et al.
Gynecologic Oncology|September 8, 2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterusAaron H Wolfson, Mark F Brady, Thomas Rocereto, et al.
Pageof 63